Trials / Unknown
UnknownNCT03565458
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Gemigliptin and Dapagliflozin or Empagliflozin in Healthy Adult Volunteers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- Male
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
gemigliptin,SGLT-2i DDI study
Detailed description
LG-DPCL018 (gemigliptin,SGLT-2i DDI study) is to evaluate the safety and immunogenicity of gemilgliptin \& dapagliflozin and gemigliptin \& empagliflozin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemigliptin | zemiglo 50mg,LG Chem |
| DRUG | Dapagliflozin | forxiga, dapagliflozin 10mg |
| DRUG | Empagliflozin | jardiance 25mg, empagliflozin |
Timeline
- Start date
- 2018-04-05
- Primary completion
- 2018-08-20
- Completion
- 2018-12-22
- First posted
- 2018-06-21
- Last updated
- 2018-06-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03565458. Inclusion in this directory is not an endorsement.